Press Releases | Investor Relations | Eledon Pharmaceuticals, Inc.

12/04/2023	Eledon Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
11/29/2023	Eledon Pharmaceuticals to Present at Noble Capital Markets' Emerging Growth Equity Conference
11/09/2023	Eledon Pharmaceuticals Reports Third Quarter 2023 Operating and Financial Results
11/08/2023	Eledon Pharmaceuticals to Present at Jefferies London Healthcare Conference
11/02/2023	Eledon Reports Updated Data from Ongoing Phase 1b Trial Evaluating Tegoprubart for Prevention of Rejection in Kidney Transplantation
10/23/2023	Eledon Pharmaceuticals Strengthens Leadership Team with Appointment of Eliezer Katz, M.D., FACS as Chief Medical Officer
10/13/2023	Eledon Pharmaceuticals to Present Data from Ongoing Phase 1b Trial of Tegoprubart in Patients Undergoing Kidney Transplantation at the American Society of Nephrology Kidney Week 2023 Annual Meeting
10/02/2023	Eledon Pharmaceuticals Appoints Kidney Transplant Specialist Dr. Allan Douglas Kirk to Board of Directors
09/25/2023	Eledon Pharmaceuticals Announces Use of Tegoprubart anti-CD40L Antibody in Second-ever Transplant of Genetically Modified Heart from a Pig to a Human
09/20/2023	Eledon Pharmaceuticals to Participate at the 2023 Cantor Fitzgerald Global Healthcare Conference